Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk

Shani Paluch-Shimon; Bella Kaufman; Ella Evron

doi:10.1007/978-3-030-24762-1_6

Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk

Shani Paluch-Shimon^*, Bella Kaufman, Ella Evron

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Young women with breast cancer are more likely to harbor a germline mutation predisposing them to cancer. The most common germline mutations among young women with breast cancer are BRCA1 and BRCA2. BRCA-associated breast cancers have unique characteristics, and BRCA1-associated tumors are more often triple-negative or basal subtype and high grade, while BRCA2-associated tumors are more commonly endocrine responsive. BRCA-associated tumors are often highly chemo-sensitive and are particularly susceptible to platinum agents and PARP inhibitors. The therapeutic impact of a germline mutation in other cancer predisposition genes is still being evaluated.

Original language	English
Title of host publication	Breast Cancer in Young Women
Publisher	Springer International Publishing
Pages	55-68
Number of pages	14
ISBN (Electronic)	9783030247621
ISBN (Print)	9783030247614
DOIs	https://doi.org/10.1007/978-3-030-24762-1_6
State	Published - 1 Jan 2020
Externally published	Yes

Keywords

BRCA1
BRCA2
Hereditary cancer
PARP inhibitors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-030-24762-1_6

Cite this

@inbook{fca4695da6dd4f9f85baf58cbe022201,

title = "Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk",

abstract = "Young women with breast cancer are more likely to harbor a germline mutation predisposing them to cancer. The most common germline mutations among young women with breast cancer are BRCA1 and BRCA2. BRCA-associated breast cancers have unique characteristics, and BRCA1-associated tumors are more often triple-negative or basal subtype and high grade, while BRCA2-associated tumors are more commonly endocrine responsive. BRCA-associated tumors are often highly chemo-sensitive and are particularly susceptible to platinum agents and PARP inhibitors. The therapeutic impact of a germline mutation in other cancer predisposition genes is still being evaluated.",

keywords = "BRCA1, BRCA2, Hereditary cancer, PARP inhibitors",

author = "Shani Paluch-Shimon and Bella Kaufman and Ella Evron",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2020.",

year = "2020",

month = jan,

day = "1",

doi = "10.1007/978-3-030-24762-1_6",

language = "אנגלית",

isbn = "9783030247614",

pages = "55--68",

booktitle = "Breast Cancer in Young Women",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk

AU - Paluch-Shimon, Shani

AU - Kaufman, Bella

AU - Evron, Ella

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2020.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Young women with breast cancer are more likely to harbor a germline mutation predisposing them to cancer. The most common germline mutations among young women with breast cancer are BRCA1 and BRCA2. BRCA-associated breast cancers have unique characteristics, and BRCA1-associated tumors are more often triple-negative or basal subtype and high grade, while BRCA2-associated tumors are more commonly endocrine responsive. BRCA-associated tumors are often highly chemo-sensitive and are particularly susceptible to platinum agents and PARP inhibitors. The therapeutic impact of a germline mutation in other cancer predisposition genes is still being evaluated.

AB - Young women with breast cancer are more likely to harbor a germline mutation predisposing them to cancer. The most common germline mutations among young women with breast cancer are BRCA1 and BRCA2. BRCA-associated breast cancers have unique characteristics, and BRCA1-associated tumors are more often triple-negative or basal subtype and high grade, while BRCA2-associated tumors are more commonly endocrine responsive. BRCA-associated tumors are often highly chemo-sensitive and are particularly susceptible to platinum agents and PARP inhibitors. The therapeutic impact of a germline mutation in other cancer predisposition genes is still being evaluated.

KW - BRCA1

KW - BRCA2

KW - Hereditary cancer

KW - PARP inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85149567974&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-24762-1_6

DO - 10.1007/978-3-030-24762-1_6

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:85149567974

SN - 9783030247614

SP - 55

EP - 68

BT - Breast Cancer in Young Women

PB - Springer International Publishing

ER -

Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this